focus -WSS

focus

author：fashion 2025-09-30 15:15:15 - browse：983

Amylyx founders — Justin Klee (left) and Joshua Cohen are the co-founders and co-CEOs of Amylyx Pharmaceuticals. Kayana Szymczak for STAT

Amylyx Pharmaceuticals said Friday that its treatment for ALS, called Relyvrio, failed to provide any benefit for patients in a large clinical trial — a stunning outcome that now has the company considering a voluntary withdrawal of the approved medicine from the market.

“This is really hard for us, and it’s really hard for our team who care so much, but it’s so much harder for people with ALS and their families, and we have to keep that perspective,” said a somber Justin Klee, Amylyx’s co-founder and co-CEO, in an interview with STAT on Thursday evening.

In the Phase 3 study involving 664 people with ALS, Relyvrio failed to outperform a placebo on an ALS functional rating scale that measures the ability to perform daily living tasks, walk, breathe, speak, and swallow. The company did not provide detailed results for the study’s primary goal, but said the calculation for statistical significance was 0.67 — well above the 0.05 threshold for success and an indication that Relyvrio provided no benefit at all.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Cancer drug shortages' outsize impact on ovarian cancer patients

leisure time

WSS

World's first CRISPR

Baltimore teen accused of firing into crowd during block party mass shooting

Morphosys mixed study results for blood cancer drug

An interview with Robert F. Kennedy Jr. on vaccines

Clinical trials must include more disabled people

CRISPR pioneers react to Casgevy, first gene

focus

focus

hotspot

What does generative AI mean for health care? We asked experts

World's first CRISPR

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Trump's false claims about Georgia's 2020 election long debunked

Apple is now the first public company to be valued at $3 trillion

Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?

Guidelines to prevent youth baseball injuries need more muscle

NYU radiologists take on the challenge of expensive MRI machines

At least 13 dead in Texas as scorching temps continue

Hilary expected to bring catastrophic, life

hotspot

The pain doctors face in trying to build their families

U.K. considers world's first use of meningitis vaccine to address gonorrhea

A daunting task: navigating dual Medicare, Medicaid eligibility

CRISPR pioneers react to Casgevy, first gene

Listen: Racing for gene therapy & a pioneering approval

Beware the threat of staffing cuts at the CDC

leisure time

focus

leisure time

Wikipedia